Instrument Inactif

Communiqués Tenax Therapeutics Inc Nasdaq

Actions

US88032L1008

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Tenax Therapeutics: Q1 Earnings Snapshot	14/05	AQ
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update	14/05	AQ
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	30/04	AQ
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	09/04	AQ
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	28/03	AQ
Tenax Therapeutics to Present at the 36th Annual Roth Conference	12/03	AQ
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	29/02	AQ
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	20/02	AQ
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	08/02	AQ
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	08/02	AQ
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	06/02	AQ
Tenax Therapeutics Announces Reverse Stock Split	29/12	AQ
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board	17/11	AQ
Tenax Therapeutics: Q3 Earnings Snapshot	14/11	AQ
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023	13/11	AQ
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	19/07/23	AQ
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	31/05/23	AQ
TENAX THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	13/04/23	AQ
Tenax Therapeutics Provides 2023 Business Update	12/04/23	AQ
TENAX THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	31/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Tenax Therapeutics Inc Nasdaq

Actions

US88032L1008

Communiqués

Filtres